Feng focuses on Deep Tech, TMT, and consumption upgrade. He led investments in Three Squirrels, Unity, 360 Finance, Qingtao Energy, Shunshun Education, 2:10 Animation, Easy Parking, Robby, and XtaiPl among others. Previously a partner at IDG-Accel, he led investments in CreditEase, Zhubajie, Prosper, Tongbanjie, Bilibili, Coinbase, Ripple Labs, Helijia, Wangli Finance Group, FraudMetrix, Liulishuo, Wecash, and others. CreditEase went public in 2015. Feng holds a B.S. in Chemistry from Peking University and an M.S. in Chemistry from the University of Rochester.
Lynn Yang
Sequoia Capital — Healthcare Investment
Prior to joining Sequoia Capital in May 2015, Lynn was on Legend Capital's healthcare team. She has led investments in Burning Rock, Cstone, Grail, and Hong Kong Asia Medical, among others. Before venture capital she was a business development manager at Johnson & Johnson and product manager at GE Healthcare. She holds an MBA from Duke University and a Master of Clinical Science from Huazhong Technology University.
Qin Yan, PhD
Director, Center for Epigenetics and Biomarkers — Yale School of Medicine
Dr. Yan is Professor and Director of the Center for Epigenetics and Biomarkers in the Department of Pathology at Yale School of Medicine, Co-Leader of the Genomics, Genetics and Epigenetics Research Program, and Scientific Co-Director of the Center for Breast Cancer at the Yale Cancer Center. He led the discovery and therapeutic targeting of KDM5 histone demethylases in cancer. NHWD-870, a bromodomain inhibitor his team reported, has entered Phase II clinical trials. PhD, University of Oklahoma; postdoctoral training with Dr. William Kaelin at Dana-Farber/Harvard.
Dr. Can Cui
Shareholder, Greenberg Traurig, LLP
Dr. Can Cui focuses on technology transactions, investments, and intellectual property protection in life sciences and med-tech, with emphasis on cross-border deals involving Asia. He represents life sciences and med-tech companies — from startups to multinationals — in U.S.–China licensing and collaboration transactions, including contract research, manufacturing, clinical trials, commercialization, and distribution. He also conducts IP due diligence for private equity and venture capital.
Gang Luo, PhD
Associate Professor of Ophthalmology, Harvard Medical School
Dr. Luo's research, drawing on his background in optics, image processing, and biomedical engineering, focuses on the human visual system and assistive technology for individuals with visual impairments. His current work includes portable collision warning devices — including smartphone-based technologies — to improve walking mobility, plus driving behavior in individuals with visual impairments.
Hui Huang, PhD, MBA
Founder & CEO, CSD-Partners LLC — Drug Development Value & Access Expert
Former Vice President, Head of Global Value & Access Oncology at Takeda (2019–2023). Head of Health Economics and Outcomes Research at Takeda Oncology / ARIAD / Millennium-Takeda (2007–2019). Senior Computational Biologist at Genome Therapeutics / AmberGen (2000–2007). MBA, Drexel University; PhD, biomedical sciences.
Zhidan Daniel Tu
COO, Zipcode Bio
Daniel oversees operations and business development at Zipcode Bio. Previously Senior Director at RVAC Medicines and Director at Legend Biotech, with extensive experience in the development and commercialization of cell and gene therapies.
